The New Yorkerのインスタグラム(newyorkermag) - 4月20日 23時01分

The first successful in-vitro fertilization, in 1978, made it possible to conceive an embryo outside the body. Today, approximately two per cent of all babies in the United States are conceived in a lab, through I.V.F.—last year, analysts valued the global I.V.F. market at more than $23 billion. Egg cells have become commodities that are harvested, bought, donated, and preserved. But egg cells, some of the most complex cells in the body, are difficult to obtain; as a woman ages, their number and quality decline.

In recent years, the science of extending female reproductive longevity has seen a new flurry of interest. Several biotech startups are in a race to figure out in-vitro gametogenesis (I.V.G.), the production of reproductive cells outside the body—and the prevailing sense is that it’s only a matter of time before one of them does. Some scientists feel that I.V.G. for human reproductive purposes may be jumping the gun—that researchers are attempting to create a process outside of reproductive organs without fully understanding what takes place inside of them. At the link in our bio, read about the future of reproductive science—and the thorny scientific, regulatory, and ethical questions it poses. Illustration by Ariel Davis (@arieldavi.s).

[BIHAKUEN]UVシールド(UVShield)

>> 飲む日焼け止め！「UVシールド」を購入する